Active Clinical Trials
We currently have the following trials open:
Principal Investigator: Anees Chagpar, MD
A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
HIC # 0705002671
Principal Investigator: Maysa Abu-Khalaf, MD
Q3 Week Carbo with Weekly Abraxane and Avastin in Resectable and Nonresectable HER2 Negative Breast Cancer
Principal Investigator: Maysa Abu-Khalaf, MD
Q3 Week Carbo with Weekly Abrax/trastuzumab in Resectable and Nonresectable HER2+ Breast Cancer
Principal Investigator: Tara Sanft, MD
Delivery of Survivorship Care Plans
Principal Investigator: Lyndsay Harris, MD
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score of 25 or Less
Principal Investigator: Erin Hofstatter, MD
A Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Postoperative Adjuvant Therapy in Node Positive or High-Risk Node Negative Breast Cancer
HIC # 0909005727 (CALBG 40502)
Principal Investigator: Lyndsay Harris, MD
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-line Therapy or Locally Recurrent or Metastatic Breast Cancer
Principal Investigator: Maysa Abu-Khalaf, MD
A Dose-escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) in Combination with Capecitabine (xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Principal Investigator: Maysa Abu-Khalaf, MD
A Phase I/Ib, Multicenter, Open-Label Study of BEZ235, Administered Orally on Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies including Patients with Advanced Breast Cancer
HIC # 1103008138
Principal Investigator: Lyndsay Harris, MDA Randomized Phase II Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
HIC # 0909005728 (CALGB 40503)
Principal Investigator: Lyndsay Harris, MDEndocrine Therapy in Combination with Anti-VEGF Therapy: A Randomized Double-blind, Placebo-controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab for Women with Hormone Receptor Positive Advanced Breast Cancer
Principal Investigator: Erin Hofstatter, MD
A Phase II Prospective Trial Correlating PFS with CYP2D6 Activity in Patients with Metastatic Breast Cancer
RTOG 0413
Principal Investigator: Joanne Weidhaas, MD, PhDRCT of APBI vs. Whole Breast Irradiation
HOPE Study
Principal Investigator: Melinda Irwin, PhDExercise Trial for Women Taking AIs Evaluating if Exercise Improves Side Effects of AIs
LEAN Study
Principal Investigator: Melinda Irwin, PhD
Weight-Loss Trial for Breast Cancer Survivors with BMI >=25 with Diet and Exercise
Yale FIT
Principal Investigator: Tish Knobf, PhDRCT of Aerobic Exercise vs. Home-based Physical Activity
Heart Strong
Principal Investigator: Tish Knobf, PhD
Cardiac Risk Assessment in Women who will Receive Anthracycline and/or Herceptin Therapy
Subclinical Lymphedema, Psychosocial and Functional Outcomes after Lymph Node Surgery
Principal Investigator: Anees Chagpar, MD
A Phase I Multiple Dwell Mammosite Trial
Principal Investigator: Joanne Weidhaas, MD, PhD
